226 related articles for article (PubMed ID: 1901071)
1. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
Rogers WJ; Babb JD; Baim DS; Chesebro JH; Gore JM; Roberts R; Williams DO; Frederick M; Passamani ER; Braunwald E
J Am Coll Cardiol; 1991 Apr; 17(5):1007-16. PubMed ID: 1901071
[TBL] [Abstract][Full Text] [Related]
2. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
Circulation; 1994 Apr; 89(4):1545-56. PubMed ID: 8149520
[TBL] [Abstract][Full Text] [Related]
3. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Anderson HV; Cannon CP; Stone PH; Williams DO; McCabe CH; Knatterud GL; Thompson B; Willerson JT; Braunwald E
J Am Coll Cardiol; 1995 Dec; 26(7):1643-50. PubMed ID: 7594098
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.
Rogers WJ; Baim DS; Gore JM; Brown BG; Roberts R; Williams DO; Chesebro JH; Babb JD; Sheehan FH; Wackers FJ
Circulation; 1990 May; 81(5):1457-76. PubMed ID: 2110033
[TBL] [Abstract][Full Text] [Related]
5. Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II).
Ruocco NA; Bergelson BA; Jacobs AK; Frederick MM; Faxon DP; Ryan TJ
J Am Coll Cardiol; 1992 Dec; 20(7):1445-51. PubMed ID: 1452916
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
7. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
TIMI Study Group
N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
[TBL] [Abstract][Full Text] [Related]
8. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
[TBL] [Abstract][Full Text] [Related]
9. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.
Rivers JT; White HD; Cross DB; Williams BF; Norris RM
J Am Coll Cardiol; 1990 Aug; 16(2):340-8. PubMed ID: 2115538
[TBL] [Abstract][Full Text] [Related]
10. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.
Grines CL; Browne KF; Marco J; Rothbaum D; Stone GW; O'Keefe J; Overlie P; Donohue B; Chelliah N; Timmis GC
N Engl J Med; 1993 Mar; 328(10):673-9. PubMed ID: 8433725
[TBL] [Abstract][Full Text] [Related]
11. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study.
Aguirre FV; Younis LT; Chaitman BR; Ross AM; McMahon RP; Kern MJ; Berger PB; Sopko G; Rogers WJ; Shaw L
Circulation; 1995 May; 91(10):2541-8. PubMed ID: 7743615
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.
Barbash GI; Roth A; Hod H; Modan M; Miller HI; Rath S; Zahav YH; Keren G; Motro M; Shachar A
Am J Cardiol; 1990 Sep; 66(5):538-45. PubMed ID: 2118299
[TBL] [Abstract][Full Text] [Related]
13. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial.
Terrin ML; Williams DO; Kleiman NS; Willerson J; Mueller HS; Desvigne-Nickens P; Forman SA; Knatterud GL; Braunwald E
J Am Coll Cardiol; 1993 Dec; 22(7):1763-72. PubMed ID: 8245326
[TBL] [Abstract][Full Text] [Related]
14. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators.
Aguirre FV; McMahon RP; Mueller H; Kleiman NS; Kern MJ; Desvigne-Nickens P; Hamilton WP; Chaitman BR
Circulation; 1994 Jul; 90(1):78-86. PubMed ID: 8026055
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
Califf RM; Topol EJ; Stack RS; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Harrelson-Woodlief L
Circulation; 1991 May; 83(5):1543-56. PubMed ID: 1902405
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of predischarge radionuclide ventriculography at rest and exercise after acute myocardial infarction treated with thrombolytic therapy or primary coronary angioplasty. The Zwolle Myocardial Infarction Study Group.
Gosselink AT; Liem AL; Reiffers S; Zijlstra F
Clin Cardiol; 1998 Apr; 21(4):254-60. PubMed ID: 9562935
[TBL] [Abstract][Full Text] [Related]
17. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
[TBL] [Abstract][Full Text] [Related]
19. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
20. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
Arnold AE; Simoons ML; Van de Werf F; de Bono DP; Lubsen J; Tijssen JG; Serruys PW; Verstraete M
Circulation; 1992 Jul; 86(1):111-20. PubMed ID: 1617763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
